Additional Details

  • Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets

    Elevate Clinical Research
    Houston TX. 77058
    View Details

  • Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets

    El Paso Pulmonary Association, PA
    El Paso TX. 79902
    View Details

  • Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets

    Clinical Research and Associates, Inc.
    Miami FL. 33126
    View Details

  • Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis

    Massachusetts General Hospital
    Boston MA. 02114
    View Details

  • Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging

    National Institutes of Health Clinical Center
    Bethesda MD. 20892
    View Details

  • FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

    Cleveland Clinic Florida
    Weston FL. 33331
    View Details

  • FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

    Essence MD Research
    Naples FL. 34102
    View Details

  • FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

    UT Health San Antonio
    San Antonio TX. 78229
    View Details

  • FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

    Yale University School of Medicine
    New Haven CT. 06520
    View Details

  • FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

    Temple University
    Philadelphia PA. 19140
    View Details

  • FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

    Institut Universitaire de Cardiologie et de Pneumologie de Quebec (IUCPQ)
    Québec G1V 4G5
    View Details

  • FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

    Henderson Clinical Trials
    Henderson NV. 89052
    View Details

  • FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

    Metroplex Pulmonary & Sleep Center
    McKinney TX. 75069
    View Details

  • FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

    University of Pittsburgh Medical Center
    Pittsburgh PA. 15213
    View Details

  • FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

    Mayo Clinic, Rochester
    Rochester MN. 55905
    View Details

  • FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

    Weill Cornell Medicine-New York-60569
    New York NY. 10021
    View Details

  • FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

    Coastal Pulmonary & Critical Care
    St. Petersburg FL. 33704
    View Details

  • FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

    University Hospitals Cleveland Medical Center
    Cleveland OH. 44106
    View Details

  • FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

    Indiana University Health Enterprise Clinical Research Operation
    Indianapolis IN. 46202
    View Details

  • FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

    Columbia University Medical Center-New York Presbyterian Hospital
    New York NY. 10032
    View Details